Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B3827388f44eeeb05bca3347565c4b691> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B3827388f44eeeb05bca3347565c4b691 NCIT_P378 "NCI" @default.
- B3827388f44eeeb05bca3347565c4b691 type Axiom @default.
- B3827388f44eeeb05bca3347565c4b691 annotatedProperty IAO_0000115 @default.
- B3827388f44eeeb05bca3347565c4b691 annotatedSource NCIT_C114103 @default.
- B3827388f44eeeb05bca3347565c4b691 annotatedTarget "A transdermal formulation containing 4-hydroxytestosterone (4-OHT), a steroidal aromatase inhibitor (AI) and androgen receptor (AR) antagonist, with potential antineoplastic activity. 4-OHT is largely converted into 4-hydroxyandrostenedione (4-OHA) and irreversibly binds to and inhibits aromatase, thereby blocking the conversion of androstenedione to estrone, and testosterone to estradiol. This may inhibit tumor cell proliferation in estrogen-dependent tumor cells. In addition, 4-OHT binds to the AR and may inhibit AR-mediated tumor cell growth. Aromatase, a cytochrome P-450 enzyme, is overexpressed in a variety of cancer cells; it plays a key role in estrogen biosynthesis. Compared to oral 4-OHT, the transdermal formulation allows for continuous release of 4-OHT into the bloodstream and prevents first pass metabolism by the liver." @default.